AstraZeneca doubles Lokelma production at its Texas facility
The pharma company invested $445m to expand its Coppell site.
List view / Grid view
The pharma company invested $445m to expand its Coppell site.
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.